• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Part 10: Multimodal Methods of Execution Infrastructure (EI) for AI Data Analyses and Exposition of the Analyses Results

Part 10: Multimodal Methods of Execution Infrastructure (EI) for AI Data Analyses and Exposition of the Analyses Results

  • Part 10 presents a 1st-in-class Corporate Application of the Novel Method.
  • Part 10 presents the Published Source(s) of this 1st-in-class  Corporate Application of this Novel Method.

10.1 Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation.

  • 1st-in-class Corporate Application of this Novel Method.

Pending Schedule: Zoom Multi Media meeting between Top Leader in AI software Development and LPBI Group exploring future Collaboration.

  • Published Source(s) of this 1st-in-class Corporate Application of the Novel Method.

Workflow for Dynamic Linkage and Transition between two Authoring Systems:

  1. LPBI Group’s WordPress.com Multi-Authors Authoring System and
  2. Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods

Authors:

  • Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief, Journal and BioMed e-Series, LPBI Group)
  • Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2026/01/06/workflow-for-dynamic-linkage-and-transition-between-two-authoring-systems-lpbi-groups-wordpress-com-multi-authors-authoring-system-and-microsoft-powerpoint-product-for-slide-show-presentation-par/

10.2 Method for Data Set Selection for Grok’s LLM & Causal Reasoning – Multimodal Data Set: Text & Images

  • 1st-in-class Corporate Application of the Novel Method.

Pilot Study Grok 4.1 and LPBI Group’s Contents

  1. 21 articles shared with UK-based TOP NLP company, 2021 – benchmarking study
  2. 20 articles selected from 3 categories of research in Cancer – Discovery study
  3. List of Articles in Book Chapters for DYAD & TRIAD Analysis, NLP and Causal Reasoning
  4. Chapters in e-Books:
  • Series A, Cardiovascular, Translational Medicine, Volume 4, Part One, Chapter 2
  • Series A, Cardiovascular, Regenerative Medicine, Volume 4, Part Two, Chapter 1
  • Series B, Genomics, Volume 1, Chapter 3
  • Series D, Immunology, Volume 3, Chapter 2

Methodologies Used for Each Row

(Full reproducibility — all tools, versions, and parameters)

Row
Method
Tools & Parameters
Notes
1
UK-based TOP NLP company, 2021
static NLP
Proprietary keyword +
co-occurrence rules
(text only)
Exact replica of 2021 run
(673 relations)
2
Grok static NLP
Regex + co-occurrence on text only
No images, no ontology
3
Grok 4.1 full multimodal
Aurora vision + LPBI ontology tree + RLHF reasoning
Text + 25 images + CSO criteria (subsets, agonist/antagonist)
4
Grok on CSO’s 20 articles from 3 categories
Same as Row 3
Category-specific weighting
5
Grok on Aviva CVD Chapter 1
Same as Row 3
Mitochondria stress focus
6
Grok on Aviva CVD Chapter 2
Same as Row 3
Stem cell regeneration focus
7
Grok on CSO Oncology Chapter 1
Same as Row 3
Cancer genomics focus
8
Grok on CSO Immunology Chapter 2
Same as Row 3
Immune development focus
9
Combined Aviva CVD Volume 4
Same as Row 3
Merged Parts 1 & 2 for regenerative cardiology

 

  • Published Source(s) of this 1st-in-class Corporate Application of the Novel Method.

2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle”

Authors:

  • Stephen J. Williams, PhD (Chief Scientific Officer, LPBI Group)
  • Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief Journal and BioMed e-Series, LPBI Group)
  • Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2025/12/15/2025-grok-4-1-causal-reasoning-multimodal-on-identical-proprietary-oncology-corpus-from-673-to-5312-novel-biomedical-relationships-a-direct-head-to-head-comparison-with-2021-static-nlp-new-foun/

10.3 Method for Data Set Selection for Grok’s LLM & Causal Reasoning – Multimodal Data Set: Audio, Text & Images

10.3.1 Data Set Selection: Audio, Text & Images

10.3.1.1 Benchmarking Grok 4.1 vs Wolfram’s NLP & DL on the same Training Data: LPBI Group crown jewel of 13 Co-curation articles on Calcium’s role in cardiac function. [Text & Images of all types of the Media Gallery.

10.3.1.2 New data Set never analyzed by AI: A set of 36 Audio Podcasts [Audio and Script] on CVD

10.3.1.3 Other articles in IP Asset Class I: The Journal on Calcium [Text and Images]

10.3.1.4 Articles from Categories of Research on Calcium and on  Atrial Fibrillation (AFib) [Text & Images]

10.3.1.5 Scoop.it Mini Vault retrievals [Text & Images]

10.3.2 Grok’s AI Modeling and Analyses Results

  • 1st-in-class Corporate Application of this Novel Method.

Forthcoming,

  • 2nd Joint Article by Aviva Lev-Ari, PhD, RN & Grok 4.1 by xAI
  • Published Source(s) of the 1st-in-class Corporate Application of the Novel Method.

2026 Grok Multimodal Causal Reasoning on Proprietary Cardiovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage

Authors:

  • Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief, Journal and BioMed e-Series, LPBI Group)
  • Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2026/01/06/2026-grok-multimodal-causal-reasoning-on-proprietary-cardiovascular-corpus-from-2021-wolfram-nlp-baseline-to-thousands-of-novel-relationships-a-second-head-to-head-validation-of-lpbi/

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI in Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
    • A Systematic Analysis of Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission – Alex Wissner-Gross Daily Newsletters by KOL (March 1 – June 10, 2026, to be extended to Present) June 11, 2026
    • In Memoriam: Professor Yitzhak Apeloig, President and Distinguised Professor of the Technion June 4, 2026
    • Top VC Investors in AI / Health AI in 2026 May 26, 2026
    • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d